Telix Pharmaceuticals (TLPPF) Retained Earnings (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Retained Earnings for 4 consecutive years, with -$110.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings changed N/A year-over-year to -$110.9 million in Q2 2026; TTM through Jun 2026 was -$110.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$154.5 million, up 49.32% from the prior year.
• Retained Earnings was -$110.9 million for Q2 2026 at Telix Pharmaceuticals, up from -$154.5 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$110.9 million in Q2 2026 and troughed at -$171.6 million in Q4 2023.
• A 4-year average of -$144.1 million and a median of -$146.9 million in 2025 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings rose 18.86% in 2024 and slipped 10.96% in 2025, its largest moves.
• Over 4 years, Retained Earnings stood at -$171.6 million in 2023, then climbed by 18.86% to -$139.3 million in 2024, then decreased by 10.96% to -$154.5 million in 2025, then grew by 28.24% to -$110.9 million in 2026.
• The last three Retained Earnings figures came in at -$110.9 million (Q2 2026), -$154.5 million (Q4 2025), and -$139.3 million (Q4 2024), per Business Quant data.